Back to search results
NCT02154022

Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

Enrolling by Invitation
Not specifiedAges 2+Observational
National Cancer Institute (NCI)
~100 participants
Updated 2026-08-31 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To obtain PK sample
Measured over study completion

Conditions

Cancer
Solid Tumors
Neoplasm

Explore related trials

Malignant NeoplasmSolid Neoplasm

NCT02154022

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • William D Figg, Pharm.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any individuals greater than or equal to 2 years of age who are currently enrolled in IRB approved NIH Intramural Research Program (IRP) clinical trials are eligible. (Exception: Participants \<18 years old will not be eligible for probe administration.)
Ability of subject or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
Individuals who have received or are anticipated to receive an investigational agent or FDA approved therapy at the NIH who meet one of the following criteria:
Individuals in whom altered pharmacokinetics are anticipated to occur based on pharmacogenetics, history of toxicities with similar agents, drug interactions, or other patient-specific factors which may alter absorption, distribution, metabolism, or excretion.

What this trial measures

  • To obtain PK samplestudy completion

    Measure drug concentrations in blood.